Key Points
- CEO Renee Gala sold 2,000 Jazz Pharmaceuticals shares at an average price of $236.40, totaling $472,800. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, leaving her with 141,394 shares.
- Jazz Pharmaceuticals reported quarterly revenue of $1.21 billion, up 15.5% year over year and above estimates, but adjusted EPS of $5.71 missed the $6.18 consensus forecast.
- Analysts remain broadly positive, with the stock carrying a consensus “Buy” rating and an average price target of $291.40, compared with a recent price of $231.19.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CEO Renee Gala sold 2,000 shares of the firm's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total value of $472,800.00. Following the sale, the chief executive officer owned 141,394 shares of the company's stock, valued at $33,425,541.60. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Trading Down 0.1%
NASDAQ:JAZZ opened at $231.19 on Thursday. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38. The business's 50-day simple moving average is $245.68 and its 200 day simple moving average is $230.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a market cap of $15.01 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 0.21 and a beta of 0.37.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.11 billion. During the same quarter in the prior year, the firm earned ($8.25) earnings per share. Jazz Pharmaceuticals's revenue for the quarter was up 15.5% compared to the same quarter last year. As a group, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.61 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the company. Triumph Capital Management increased its stake in shares of Jazz Pharmaceuticals by 2.0% in the second quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company's stock valued at $626,000 after purchasing an additional 52 shares during the period. Bessemer Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock worth $4,228,000 after buying an additional 73 shares during the period. Fifth Third Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 4.4% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company's stock valued at $377,000 after acquiring an additional 85 shares during the period. Root Financial Partners LLC increased its position in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock valued at $56,000 after acquiring an additional 89 shares during the period. Finally, Syon Capital LLC grew its stake in shares of Jazz Pharmaceuticals by 7.4% in the second quarter. Syon Capital LLC now owns 1,507 shares of the specialty pharmaceutical company's stock worth $363,000 after purchasing an additional 104 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 3rd. Wells Fargo & Company boosted their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a report on Tuesday, August 4th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an "overweight" rating in a research report on Wednesday, August 26th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $291.40.
Check Out Our Latest Research Report on JAZZ
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.
Jazz's neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
